Survival after immunotherapy for advanced lung adenocarcinoma does not have definitive data at this time, and patients for whom immunotherapy is effective generally experience prolonged survival. The overall survival of patients with advanced lung adenocarcinoma is not long, and data report that the five-year survival rate of patients is about 10%, a figure that suggests that the majority of patients with advanced lung adenocarcinoma do not survive for more than five years. Therefore, in order to improve the survival time of patients, according to the different situations of gene mutation and immune expression, patients with advanced lung adenocarcinoma should choose targeted drugs, immune drugs or chemotherapeutic drugs for the treatment of lung adenocarcinoma lesions, and patients with effective treatments can obviously alleviate the clinical symptoms and prolong the survival time of the patients, but the specific treatments need to be in accordance with the instructions of the doctor.